Related Experiment Videos
DX-9065a Daiichi
1Friedrich Schiller University Jena, Center for Vascular Biology and Medicine, Nordhäuser Str 78, D-99089 Erfurt, Germany. kaiser@zmkh.ef.uni-jena.de
Current Opinion in Investigational Drugs (London, England : 2000)
|October 30, 2003
Abstract:
DX-9065a is a Factor Xa inhibitor under development by Daiichi as an anticoagulant for the potential treatment of cardiovascular indications, including thrombosis and angina. By March 1996, DX-9065a had entered phase I trials in Japan and Europe, and by November 1998, it was in phase II trials in Japan. In February 2003, phase II trials for the prevention of myocardial infarction in patients with unstable angina pectoris were ongoing in Japan, Europe and the US.